{"product_id":"idya-ansoff-analysis","title":"(IDYA) IDEAYA Biosciences, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis IDEAYA Biosciences, Inc. Ansoff Matrix Analysis shows practical growth options across market penetration, market development, product development, and diversification to inform strategy, investing, or planning. The page already includes a real preview\/sample of the analysis so you can judge the format and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE397 Phase I MTAP-deleted solid tumor enrollment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE397’s Phase I solid-tumor program targets the MTAP-deleted subset, which appears in about 10% to 15% of cancers, so the Ansoff move is deeper penetration inside an existing precision-oncology pool. More site activation and faster screening can lift enrollment in this same biomarker-defined segment and help IDEAYA Biosciences, Inc. capture a bigger share of eligible patients without changing the core indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE196 Phase I\/II GNAQ\/GNA11-mutant cancer reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE196 is in Phase I\/II for GNAQ\/GNA11-mutant cancers, with the main fit in metastatic uveal melanoma, where GNAQ\/GNA11 alterations drive about 80% to 90% of cases. This is market penetration, not new-market play: IDEAYA Biosciences, Inc. is deepening use in the same mutation-defined niche. The upside comes from more trial sites and, if data hold, a larger share of a small but highly targeted patient pool.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiomarker-led patient selection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. uses biomarker-led patient selection to narrow trial and treatment pools to the exact molecular subsets it can target. In current oncology markets, this is a direct penetration lever: MTAP-deleted tumors are about 10% to 15% of solid tumors, so tighter screening lifts the hit rate from broad tumor populations into addressable patients. That improves trial efficiency and commercial conversion without changing the core market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePfizer-backed development in uveal melanoma and melanoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s Pfizer-backed Phase I\/II work strengthens reach in metastatic uveal melanoma, skin melanoma, and other solid tumors. Uveal melanoma is rare, with about 2,000 U.S. cases a year, while skin melanoma exceeds 100,000 annual U.S. cases, so even small share gains matter. The Pfizer supply and development deal can speed trial scale and deepen IDEAYA’s grip in these existing oncology markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePhase I\/II Pfizer support\u003c\/li\u003e\n\u003cli\u003eTargets existing oncology segments\u003c\/li\u003e\n\u003cli\u003eUveal melanoma: ~2,000 U.S. cases\u003c\/li\u003e\n\u003cli\u003eSkin melanoma: 100,000+ U.S. cases\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSynthetic lethality focus in precision oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. stays tightly focused on synthetic lethality, so its market penetration grows by deepening one precision-oncology niche instead of chasing broad tumor classes. That model helps it reuse the same investigators, biomarker tests, and trial sites across programs, which lowers friction and can speed enrollment in a crowded 2025-2026 oncology trial base. In 2025, that focus also mattered because IDEAYA had multiple synthetic-lethality programs in the clinic, reinforcing specialist credibility with the same prescriber and research network.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame niche, same investigators, same biomarker workflow.\u003c\/li\u003e\n\u003cli\u003eRepeat use can improve trial speed and trust.\u003c\/li\u003e\n\u003cli\u003eFocused pipeline supports clearer partner talks.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA Targets Smaller, Deeper Biomarker-Cancer Pools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is using market penetration by pushing the same biomarker-defined oncology pools harder, not entering new ones. IDE397 targets MTAP-deleted tumors, about 10%-15% of solid cancers, and IDE196 targets GNAQ\/GNA11-mutant cancers, which drive about 80%-90% of metastatic uveal melanoma.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003e2025\/2026\u003c\/th\u003e\n\u003cth\u003ePool\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE397\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003e10%-15%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE196\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II\u003c\/td\u003e\n\u003ctd\u003e80%-90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines IDEAYA Biosciences, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Ansoff Matrix view of IDEAYA Biosciences’ growth options for faster strategy alignment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites authoritative filings, trial data, investor materials, and industry reports to fast-verify IDEAYA’s Ansoff growth assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE397 expansion across MTAP-deleted solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE397 is already in MTAP-deleted solid tumors, so market development means using the same biomarker across more tumor types without changing the drug’s core biology. MTAP deletion is found in about 10% to 15% of solid tumors, which widens the addressable patient pool. IDEAYA Biosciences, Inc. can scale reach from one niche to a broader biomarker-defined market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE196 reach into broader genetically defined cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE196 is a market-development play because it turns one molecule into a broader, mutation-defined cancer platform. GNAQ or GNA11 mutations drive about 80% of uveal melanoma, and expanding into other mutation-positive tumors can open a new patient pool beyond the core niche. IDEAYA reported about $841 million in cash and investments at 2025 year-end, supporting this expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePfizer collaboration for metastatic uveal melanoma, skin melanoma, and other solid tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePfizer collaboration is a Market Development move: one alliance now spans 3 tumor groups—metastatic uveal melanoma, skin melanoma, and other solid tumors—so IDEAYA Biosciences, Inc. can push the same portfolio into new clinical segments. That broadens addressable use without rebuilding the asset base, which lowers launch risk and can lift peak sales from one program. In 2025, IDEAYA reported continued pipeline expansion across these settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUK research linkage through Cancer Research UK and the University of Manchester\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s PARG inhibitor work with Cancer Research UK and the University of Manchester gives it a new external R\u0026amp;D base and wider access to UK oncology expertise. The UK has a 67.7 million population and a deep cancer-research network, so this partnership can broaden discovery reach beyond South San Francisco.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew UK R\u0026amp;D access\u003c\/li\u003e\n\u003cli\u003eBroader oncology reach\u003c\/li\u003e\n\u003cli\u003eStronger partner-led research\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic alliance with GlaxoSmithKline plc\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s alliance with GlaxoSmithKline plc widens its reach through GSK’s global development and commercial network, making this a clear market-development move. GSK reported £31.4 billion in 2024 sales, showing the scale behind that channel. For IDEAYA, the partnership can speed clinical access and de-risk expansion without building a bigger field force. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses GSK’s global trial network\u003c\/li\u003e\n\u003cli\u003eExpands reach beyond IDEAYA alone\u003c\/li\u003e\n\u003cli\u003eLowers go-to-market build costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA Expands Biomarker Plays With Strong Cash Backing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is using market development to widen each biomarker play into more tumors without changing the core drug. IDE397 targets MTAP-deleted solid tumors, a pool seen in about 10% to 15% of solid tumors, while IDE196 extends into other GNAQ or GNA11-driven cancers, which cause about 80% of uveal melanoma. Cash and investments were about $841 million at 2025 year-end.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eMarket move\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE397\u003c\/td\u003e\n\u003ctd\u003eBroader MTAP use\u003c\/td\u003e\n\u003ctd\u003e10% to 15% of solid tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE196\u003c\/td\u003e\n\u003ctd\u003eMore mutation-defined cancers\u003c\/td\u003e\n\u003ctd\u003eAbout 80% of uveal melanoma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBalance sheet\u003c\/td\u003e\n\u003ctd\u003eSupports expansion\u003c\/td\u003e\n\u003ctd\u003e$841 million at 2025 year-end\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eIDEAYA Biosciences, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. It maps IDEAYA Biosciences’ growth options across market penetration, product development, market development, and diversification with actionable insights and risk notes. The full, editable version is available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE397 MAT2A inhibitor progression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE397 is IDEAYA Biosciences’ MAT2A inhibitor, so its progression is a new product move inside the same precision-oncology niche. The program is tightly biomarker-led for MTAP-deleted tumors, a loss seen in about 10%-15% of solid tumors, which narrows the target pool but improves patient selection. That keeps the asset aligned with a focused, high-value oncology strategy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDE196 PKC inhibitor progression\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDE196, a protein kinase C inhibitor, is a product expansion move for IDEAYA Biosciences in genetically defined cancers. Its Phase I\/II program targets GNAQ and GNA11-mutant tumors, including uveal melanoma, aiming at a clearly segmented oncology niche. This builds a differentiated product around a biomarker-led approach, with IDEAYA reporting 1Q 2025 cash and investments of $788.5 million.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePARG inhibitor program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.'s earlier-stage PARG inhibitor program adds a new small-molecule oncology candidate and fits Ansoff's product development path: new products for existing cancer markets. The biomarker-led design targets tumors with specific genetic or molecular drivers, which can sharpen patient selection and raise response odds. In a pipeline with 1 new mechanism, this helps widen IDEAYA Biosciences, Inc.'s precision-oncology reach without changing its core focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePol Theta inhibitor program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA’s Pol theta inhibitor program targets BRCA and other homologous recombination deficiency tumors, adding a new DNA-repair branch to its synthetic lethality platform. BRCA1\/2 mutations appear in about 5%-10% of breast cancers and 15%-20% of ovarian cancers, so the addressable pool is real and tied to validated biology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDistinct DNA-repair expansion\u003c\/li\u003e\n\u003cli\u003eFits synthetic lethality strategy\u003c\/li\u003e\n\u003cli\u003eTargets BRCA\/HRD cancers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWRN inhibitor program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is extending its product development strategy with a WRN inhibitor for MSI-H tumors, a biomarker-selected cancer group. MSI-H shows up in about 3% to 5% of solid tumors, so the program targets a defined niche rather than a broad market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew precision-oncology product\u003c\/li\u003e\n\u003cli\u003eTargets MSI-H biomarker group\u003c\/li\u003e\n\u003cli\u003eDeepens IDEAYA's pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis fits Ansoff product development: same oncology focus, new pipeline asset. It can broaden IDEAYA Biosciences, Inc.'s future mix beyond one program set and add another shot at a high-value, genomically defined cancer segment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA’s Precision-Oncology Pipeline Expands With Strong Cash Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc.’s product development is classic Ansoff: new precision-oncology drugs for the same cancer market. In 1Q 2025, cash and investments were $788.5 million, which supports multiple mid-stage shots. IDE397, IDE196, PARG, Pol theta, and WRN all widen the pipeline around biomarker-selected tumors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE397\u003c\/td\u003e\n\u003ctd\u003eNew product\u003c\/td\u003e\n\u003ctd\u003eMTAP-deleted tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDE196\u003c\/td\u003e\n\u003ctd\u003eExpansion\u003c\/td\u003e\n\u003ctd\u003e1Q 2025 cash $788.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWRN\u003c\/td\u003e\n\u003ctd\u003eNew niche\u003c\/td\u003e\n\u003ctd\u003eMSI-H tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePARG inhibitor research with Cancer Research UK and Manchester\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is advancing its PARG inhibitor with Cancer Research UK and the University of Manchester, linking one new oncology asset to a new external research network. In Ansoff terms, this is diversification: a new product built through a partnership-led model, not a simple line extension. It also broadens IDEAYA’s target pool beyond its core programs, adding 1 more early-stage research route.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMultiple synthetic lethality targets beyond the lead assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is not tied only to IDE397 and IDE196; it also advances PARG, Pol Theta, and WRN programs. That gives it at least three more synthetic-lethality shots across distinct target classes and biomarker-linked tumor markets. The spread lowers single-asset risk and broadens the upside if one program misses.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharma alliance model with Pfizer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIDEAYA’s Pfizer alliance shifts Phase I\/II clinical development and supply to a partner, instead of an internal-only path. That diversifies execution risk across 2 companies and can speed oncology asset work. For IDEAYA, it also broadens development capacity without building every clinical and manufacturing step in-house.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eStrategic alliance with GlaxoSmithKline plc\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe GlaxoSmithKline plc alliance gives IDEAYA Biosciences, Inc. a second major pharma development channel, alongside Pfizer, so the company can spread future programs across 2 large partners instead of 1. That lowers single-partner dependence and supports diversification in Ansoff Matrix terms, because IDEAYA can use the same science platform in a broader execution model. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2 major pharma partners: GSK and Pfizer\u003c\/li\u003e\n\u003cli\u003eLess reliance on one deal path\u003c\/li\u003e\n\u003cli\u003eMore options for future program launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBroad biomarker portfolio across MTAP, GNAQ\/GNA11, BRCA\/HRD, and MSI-H\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is diversifying across four biomarker-led markets: MTAP deletions, GNAQ\/GNA11 mutations, BRCA\/HRD, and MSI-H. That is a clear Ansoff diversification play, because it expands into new molecular segments and multiple product classes, not just one disease niche. The mix also reduces dependence on any single tumor biology.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour biomarker groups\u003c\/li\u003e\n\u003cli\u003eNew molecular markets\u003c\/li\u003e\n\u003cli\u003eMultiple product classes\u003c\/li\u003e\n\u003cli\u003eLower single-target risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIDEAYA Diversifies Beyond Core with 2 Partners and 4 Biomarker Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIDEAYA Biosciences, Inc. is using diversification in Ansoff terms by pushing beyond its core assets into partnered new programs like PARG, adding a second pharma channel with Pfizer and GSK. It also spans four biomarker markets: MTAP, GNAQ\/GNA11, BRCA\/HRD, and MSI-H. That spreads execution and biology risk across 2 major partners and 4 target groups.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eCount\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMajor pharma partners\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiomarker groups\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew external research route\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234490720521,"sku":"idya-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/idya-ansoff-matrix.webp?v=1785721644","url":"https:\/\/dcfanalyst.com\/products\/idya-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}